Search alternatives:
_aps decrease » _ decrease (Expand Search), a decrease (Expand Search)
ra decreased » a decreased (Expand Search), pa decreased (Expand Search), la decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
point ra » point _ (Expand Search), point p (Expand Search), points a (Expand Search)
point c » point _ (Expand Search), point p (Expand Search), points _ (Expand Search)
_aps decrease » _ decrease (Expand Search), a decrease (Expand Search)
ra decreased » a decreased (Expand Search), pa decreased (Expand Search), la decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
point ra » point _ (Expand Search), point p (Expand Search), points a (Expand Search)
point c » point _ (Expand Search), point p (Expand Search), points _ (Expand Search)
-
1
-
2
Prb1 overexpression decreased APCs in ESCRT-mutant cells after nitrogen starvation.
Published 2022“…Over 600 cells were counted for each strain. <b>C.</b> GFP-Atg8 degradation in ESCRT- mutant cells increased with Prb1 overexpression. …”
-
3
Pep4 overexpression decreased APCs in Vps21- and ESCRT-mutant cells after nitrogen starvation.
Published 2022“…P values in panels C, D, and F: n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001. …”
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Percentage decrease in the performance parameters of Type B & Type C modules (Eff. & FF degradation is in percentage points).
Published 2022“…<p>Percentage decrease in the performance parameters of Type B & Type C modules (Eff. & FF degradation is in percentage points).…”
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
Published 2019“…Participants were randomised to anakinra or to a TNFi (i.e., adalimumab, certolizumab pegol, etanercept, infliximab, or golimumab), and the primary end point was the change in percentage of glycated haemoglobin (HbA1c%) (EudraCT: 2012-005370-62 ClinicalTrial.gov: NCT02236481).…”